EGFR and squamous cell carcinoma: However, previous studies showed that the ORR of combination therapy in patients with exon 21 L858 mutation was lower than in patients with exon 19 deletion.11 In addition, one patient with PD in the combination group of our study had squamous cell carcinoma with EGFR mutation.